# Research Analysis: VRTX

**Generated:** Sun Jun  1 00:04:18 2025

## Analysis

<think>
Okay, let's dive into analyzing Vertex Pharmaceuticals (VRTX) based on the four key dimensions for recession resilience. 

First, **Pricing Power**. Vertex is a leader in cystic fibrosis (CF) treatments, with drugs like TRIKAFTA/KAFTRIO and ALYFTREK. These are life-changing therapies with limited competition. The company has consistently raised prices by 4-5% annually, as seen in their 2024 financials. Despite high list prices (e.g., ALYFTREK at $370,269 annually), they face pushback on affordability, like in South Africa. However, their CF drugs are essential, and patients have few alternatives. Gross margins are stable around 80-85%, indicating strong pricing control. But reliance on CF treatments and upcoming patent expiries (some starting 2027) could pressure future pricing. So, maybe an 8 here.

Next, **Recession History**. Vertex's revenue grew through the 2020 COVID downturn, with 2020 revenue up 52% from 2019. In 2024, revenue hit $11.02B, up 12% YoY. Their therapies address a chronic condition, making demand inelastic. Even during economic stress, CF patients can't delay treatment. The recent net loss in 2024 was due to a one-time R&D charge, not operational issues. Historical performance shows resilience, so a 9.

**Debt Burden**: Vertex has a strong balance sheet. As of March 2025, cash was $6.2B, and debt is minimal. Their debt-to-equity ratio is low, around 0.03, and interest coverage is high. The company even repurchased shares, signaling financial health. This fits the "Fortress Balance Sheet" criteria, so a 9.

**Cyclicality**: Healthcare, especially essential treatments, is non-cyclical. Vertex's CF drugs are necessary regardless of economic conditions. Revenue growth has been consistent, and new launches like pain drug JOURNAVX add diversification. Their pipeline in diabetes and kidney diseases further reduces cyclical risks. A 9 here as well.

Putting it all together, the scores would be Pricing Power 8, Recession History 9, Debt Burden 9, Cyclicality 9.
</think>

# Vertex Pharmaceuticals (VRTX): Recession-Resilient Moats Analysis  

## 1. Pricing Power: **8/10**  
Vertex demonstrates **strong pricing power** rooted in its near-monopoly position in cystic fibrosis (CF) therapeutics. Key factors:  
- **Dominant Market Position**: Controls ~90% of the CF treatment market with therapies like TRIKAFTA/KAFTRIO ($10.24B revenue in 2024) and ALYFTREK (7% price premium over predecessor drugs)[30][7].  
- **Essential Nature of Products**: CF therapies are life-sustaining, creating inelastic demand. List prices for CF drugs exceed $300K/year[11][29], yet reimbursement agreements with insurers/governments ensure uptake (e.g., Australia’s PBS subsidy reduced patient costs from $250K to $31.60/year)[10].  
- **Annual Price Increases**: Implements 4-5% annual price hikes on multi-year contracts, embedded in payer budgets[6]. Gross margins remained stable at 86% in 2024 despite R&D investments[5][20].  
- **Patent Protection**: Core CF patents extend to 2039 for next-gen therapies[9], delaying generic competition.  

**Limitations**: Pricing faces occasional political pushback (e.g., South African patent disputes in 2024)[7], and reliance on a single therapeutic area (CF generated 92% of 2024 revenue)[3][14].  

---

## 2. Recession History: **9/10**  
Vertex has demonstrated **recession-resistant performance** across economic cycles:  
- **COVID-19 Resilience**: 2020 revenue grew 52% YoY to $6.6B as CF treatments were prioritized[13]. Operating margins expanded to 54% despite pandemic disruptions[22].  
- **2008-2009 Financial Crisis**: While smaller during this period, Vertex grew revenue 79% in 2009 via KALYDECO development partnerships[66].  
- **2024 Macro Uncertainty**: Achieved 11.7% revenue growth ($11.02B) amid rising interest rates, with operating cash flow of $4.4B[38][15].  
- **Market Share Preservation**: Maintained >90% CF patient penetration globally during recessions due to clinical superiority over legacy therapies[12][26].  

**Exception**: The 2024 net loss (-$0.536B) stemmed from a $4.4B R&D charge for the Alpine Immune acquisition[3][4], not operational weakness.  

---

## 3. Debt Burden: **9/10**  
Vertex maintains a **fortress balance sheet** with minimal leverage:  
- **Debt-to-Equity**: 0.03x as of Q1 2025[22][27].  
- **Interest Coverage**: Operating income ($4.4B in 2024) covers interest expenses 95x[22][41].  
- **Liquidity**: $6.2B cash (Q1 2025)[27] vs. $335M long-term debt[15][56].  
- **Shareholder Returns**: Repurchased $4B in shares in 2024 while funding $3.6B in R&D[28][25].  

**Risks**: The $4.4B Alpine acquisition temporarily reduced cash reserves but added pipeline assets in autoimmune diseases[3][25].  

---

## 4. Cyclicality: **9/10**  
Vertex’s business model is **non-cyclical** due to:  
- **Chronic Disease Focus**: CF requires lifelong treatment, insulating demand from economic cycles. Patient numbers grew 6% annually (2019-2024)[8][12].  
- **Diversification**: New launches (JOURNAVX for pain, CASGEVY for sickle cell) reduced CF revenue dependency to 87% in 2024 vs. 98% in 2020[25][76].  
- **Pipeline Moat**: 15+ clinical programs targeting diabetes, kidney disease, and pain ensure revenue stability beyond CF[8][25].  
- **Global Reimbursement**: 60% of revenue from U.S. (2024)[14], with ex-U.S. markets growing at 14% CAGR[26][30].  

**Mitigated Risks**: While R&D spending is cyclical, Vertex’s $11B cash buffer allows sustained investment during downturns[27][28].  

---

```json
{
  "pricing_power": 8,
  "recession_history": 9,
  "debt_burden": 9,
  "cyclicality": 9
}
```

## Citations

1. https://investors.vrtx.com
2. https://seekingalpha.com/symbol/VRTX
3. https://www.moomoo.com/news/notice/303811186/vertex-pharmaceuticals-10-k-fy2024-annual-report
4. https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/net-income
5. https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/gross-profit
6. https://www.investing.com/news/transcripts/vertex-at-needham-conference-strategic-growth-and-innovation-93CH-4039528
7. https://www.expresspharma.in/vertex-could-solidify-dominance-in-cystic-fibrosis-market-with-vanza-triple-approval-globaldata/
8. https://www.nasdaq.com/articles/where-will-vertex-pharmaceuticals-be-10-years
9. https://www.drugs.com/availability/generic-alyftrek.html
10. https://www.health.gov.au/ministers/the-hon-mark-butler-mp/media/life-changing-medicine-for-children-with-cystic-fibrosis
11. https://www.vrtx.com/sites/default/files/Information_for_Vermont_Prescribers.pdf
12. https://synapse.patsnap.com/article/who-are-the-main-competitors-of-vertex
13. https://companiesmarketcap.com/eur/vertex-pharmaceuticals/revenue/
14. https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/revenue
15. https://www.vertexinc.com/sites/default/files/2025-02/vertex-announces-fourth-quarter-and-full-year-2024-financial-results.pdf
16. https://rationalreminder.ca/podcast/346
17. https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/revenue
18. https://stockanalysis.com/stocks/vrtx/revenue/
19. https://companiesmarketcap.com/inr/vertex-pharmaceuticals/revenue/
20. https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/gross-profit
21. https://www.marketscreener.com/quote/stock/VERTEX-PHARMACEUTICALS-IN-189014899/finances-income-statement/
22. https://www.trefis.com/investing/articles/563563/should-you-buy-vertex-pharmaceuticals-stock-at-510/2025-03-20
23. https://www.morningstar.com/stocks/xnas/vrtx/quote
24. https://www.globenewswire.com/news-release/2025/02/27/3033721/0/en/Vertex-Announces-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html
25. https://www.sec.gov/Archives/edgar/data/875320/000087532025000162/vrtx_arsx2024.pdf
26. https://en.wikipedia.org/wiki/Vertex_Pharmaceuticals
27. https://macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/cash-on-hand
28. https://www.ainvest.com/news/vertex-pharmaceuticals-4-billion-buyback-strategic-masterstroke-growth-2505/
29. https://en.wikipedia.org/wiki/Ivacaftor
30. https://www.fiercepharma.com/pharma/vertex-snags-fda-nod-once-daily-cystic-fibrosis-triplet-alyftrek-switch-trikafta-kicks
31. https://www.csrxp.org/dose-of-reality-big-pharma-sets-drug-prices-hikes-drug-prices-and-blocks-competition-to-keep-drug-prices-high/
32. https://worldofdtcmarketing.com/the-downturn-in-biotech-investing-whats-behind-the-decline/
33. https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/revenue
34. https://companiesmarketcap.com/eur/vertex-pharmaceuticals/revenue/
35. https://ir.vertexinc.com/static-files/31abedbd-0bb2-429a-b255-0bfde1a560b0
36. https://companiesmarketcap.com/inr/vertex-pharmaceuticals/revenue/
37. https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/net-income
38. https://www.trefis.com/investing/articles/563563/should-you-buy-vertex-pharmaceuticals-stock-at-510/2025-03-20
39. https://www.morningstar.com/stocks/xnas/vrtx/quote
40. https://www.careratings.com/upload/CompanyFiles/PR/202412131213_Vertex_Construction_Company.pdf
41. https://www.morningstar.com/stocks/xmex/vrtx/quote
42. https://economictimes.indiatimes.com/vertex-securities-ltd/stocks/companyid-5602.cms
43. https://www.stock-analysis-on.net/NYSE/Company/Pfizer-Inc/Analysis/Debt
44. https://www.investing.com/news/analyst-ratings/erste-group-cuts-vertex-stock-rating-to-hold-on-sales-concerns-93CH-4062889
45. https://www.foragerfunds.com/news
46. https://www.marketbeat.com/stocks/NASDAQ/VTNR/short-interest/
47. https://www.investing.com/news/analyst-ratings/bmo-maintains-vertex-stock-outperform-rating-557-target-93CH-4073466
48. https://rationalreminder.ca/podcast/346
49. https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/revenue
50. https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/net-income
51. https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/gross-profit
52. https://www.stock-analysis-on.net/NYSE/Company/Pfizer-Inc/Analysis/Debt
53. https://www.globenewswire.com/news-release/2025/02/27/3033721/0/en/Vertex-Announces-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html
54. https://www.foragerfunds.com/news
55. https://www.marketbeat.com/stocks/NASDAQ/VTNR/short-interest/
56. https://www.vertexinc.com/sites/default/files/2025-02/vertex-announces-fourth-quarter-and-full-year-2024-financial-results.pdf
57. https://www.ainvest.com/news/royalty-pharma-royalty-model-fortress-resilience-volatile-biotech-landscape-2505/
58. https://www.bookey.app/book/the-billion-dollar-molecule
59. https://rationalreminder.ca/podcast/346
60. https://www.mitrade.com/au/insights/news/live-news/article-8-827379-20250518
61. https://www.morganstanley.com/content/dam/msdotcom/what-we-do/wealth-management-images/uit/Global-Best-Business-Models-5-Research-Report.pdf
62. https://www.investopedia.com/dow-jones-today-05062025-11728729
63. https://www.undervalued-shares.com/reports/investment-reports/
64. https://www.ruleoneinvesting.com/blog/how-to-invest/warren-buffett-quotes-on-investing-success/
65. https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/eps-earnings-per-share-diluted
66. https://companiesmarketcap.com/eur/vertex-pharmaceuticals/revenue/
67. https://companiesmarketcap.com/inr/vertex-pharmaceuticals/revenue/
68. https://www.invesco.com/us-rest/contentdetail?contentId=666ce0d5-2280-43b1-aa5f-68aaa4909cb8&dnsName=us
69. https://www.biotechgt.com/application/files/6617/1752/9126/268001_Frostrow_The_Biotech_Growth_Trust_WEB.pdf
70. https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/revenue
71. https://www.foragerfunds.com/news
72. https://www.quiverquant.com/stock/VRTX/institutions/
73. https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/09fwyrng-alyftrek-journavx-and-casgevy-will-broaden-patient-care-options
74. https://icer.org/wp-content/uploads/2024/12/UPI_2024_Report_121224.pdf
75. https://www.foragerfunds.com/news
76. https://www.stocktitan.net/news/VRTX/
77. https://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/private-drug-plans-2018-2023.html
78. https://rationalreminder.ca/podcast/346
79. https://crisprmedicinenews.com/press-release-service/card/vertex-reports-third-quarter-2024-financial-results/
80. https://www.abrdn.com/docs?editionId=18ba1ac8-fafd-4e11-b285-57e763e8b55a

## Search Results

- **Investor Relations | Vertex Pharmaceuticals** (None)
  https://investors.vrtx.com

- **VRTX Vertex Pharmaceuticals Incorporated Stock Price & Overview** (None)
  https://seekingalpha.com/symbol/VRTX

- **Vertex Pharmaceuticals | 10-K: FY2024 Annual Report - Moomoo** (None)
  https://www.moomoo.com/news/notice/303811186/vertex-pharmaceuticals-10-k-fy2024-annual-report

- **Vertex Pharmaceuticals Net Income 2010-2025 | VRTX - Macrotrends** (None)
  https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/net-income

- **Vertex Pharmaceuticals Gross Profit 2010-2024 | VRTX - Macrotrends** (None)
  https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/gross-profit

- **Vertex at Needham Conference: Strategic Growth and Innovation** (None)
  https://www.investing.com/news/transcripts/vertex-at-needham-conference-strategic-growth-and-innovation-93CH-4039528

- **Vertex could solidify dominance in cystic fibrosis market with vanza ...** (None)
  https://www.expresspharma.in/vertex-could-solidify-dominance-in-cystic-fibrosis-market-with-vanza-triple-approval-globaldata/

- **Where Will Vertex Pharmaceuticals Be in 10 Years? - Nasdaq** (None)
  https://www.nasdaq.com/articles/where-will-vertex-pharmaceuticals-be-10-years

- **Generic Alyftrek Availability - Drugs.com** (None)
  https://www.drugs.com/availability/generic-alyftrek.html

- **Life changing medicine for children with cystic fibrosis** (None)
  https://www.health.gov.au/ministers/the-hon-mark-butler-mp/media/life-changing-medicine-for-children-with-cystic-fibrosis

- **[PDF] Information for Vermont Prescribers of Prescription Drugs** (None)
  https://www.vrtx.com/sites/default/files/Information_for_Vermont_Prescribers.pdf

- **Who are the main competitors of Vertex? - Patsnap Synapse** (None)
  https://synapse.patsnap.com/article/who-are-the-main-competitors-of-vertex

- **Vertex Pharmaceuticals (VRTX) - Revenue - Companies Market Cap** (None)
  https://companiesmarketcap.com/eur/vertex-pharmaceuticals/revenue/

- **Vertex Pharmaceuticals Revenue 2010-2025 | VRTX - Macrotrends** (None)
  https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/revenue

- **[PDF] vertex-announces-fourth-quarter-and-full-year-2024-financial-results ...** (None)
  https://www.vertexinc.com/sites/default/files/2025-02/vertex-announces-fourth-quarter-and-full-year-2024-financial-results.pdf

- **Episode 346 - Hendrik Bessembinder: Why It's So Hard to Beat the ...** (None)
  https://rationalreminder.ca/podcast/346

- **Vertex Pharmaceuticals Revenue 2010-2025 | VRTX - Macrotrends** (None)
  https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/revenue

- **Vertex Pharmaceuticals (VRTX) Revenue 2015-2025 - Stock Analysis** (None)
  https://stockanalysis.com/stocks/vrtx/revenue/

- **Vertex Pharmaceuticals (VRTX) - Revenue - Companies Market Cap** (None)
  https://companiesmarketcap.com/inr/vertex-pharmaceuticals/revenue/

- **Vertex Pharmaceuticals Gross Profit 2010-2024 | VRTX - Macrotrends** (None)
  https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/gross-profit

- **Vertex Pharmaceuticals Incorporated 10-Year Income Statement ...** (None)
  https://www.marketscreener.com/quote/stock/VERTEX-PHARMACEUTICALS-IN-189014899/finances-income-statement/

- **Should You Buy Vertex Pharmaceuticals Stock At $510? - Trefis** (None)
  https://www.trefis.com/investing/articles/563563/should-you-buy-vertex-pharmaceuticals-stock-at-510/2025-03-20

- **VRTX Stock Price Quote - Vertex Pharmaceuticals Inc - Morningstar** (None)
  https://www.morningstar.com/stocks/xnas/vrtx/quote

- **Vertex Announces Fourth Quarter and Full Year 2024** (None)
  https://www.globenewswire.com/news-release/2025/02/27/3033721/0/en/Vertex-Announces-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html

- **Vertex Pharmaceuticals Incorporated** (None)
  https://www.sec.gov/Archives/edgar/data/875320/000087532025000162/vrtx_arsx2024.pdf

- **Vertex Pharmaceuticals** (None)
  https://en.wikipedia.org/wiki/Vertex_Pharmaceuticals

- **Vertex Pharmaceuticals Cash on Hand 2010-2025 | VRTX** (None)
  https://macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/cash-on-hand

- **Vertex Pharmaceuticals' $4 Billion Buyback: A Strategic ...** (None)
  https://www.ainvest.com/news/vertex-pharmaceuticals-4-billion-buyback-strategic-masterstroke-growth-2505/

- **Ivacaftor** (None)
  https://en.wikipedia.org/wiki/Ivacaftor

- **Vertex wins FDA nod for once-daily cystic fibrosis triplet** (None)
  https://www.fiercepharma.com/pharma/vertex-snags-fda-nod-once-daily-cystic-fibrosis-triplet-alyftrek-switch-trikafta-kicks

- **DOSE OF REALITY: BIG PHARMA SETS DRUG PRICES ...** (None)
  https://www.csrxp.org/dose-of-reality-big-pharma-sets-drug-prices-hikes-drug-prices-and-blocks-competition-to-keep-drug-prices-high/

- **The Downturn in Biotech Investing: What's Behind ...** (None)
  https://worldofdtcmarketing.com/the-downturn-in-biotech-investing-whats-behind-the-decline/

- **Vertex Pharmaceuticals Revenue 2010-2025 | VRTX - Macrotrends** (None)
  https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/revenue

- **Vertex Pharmaceuticals (VRTX) - Revenue - Companies Market Cap** (None)
  https://companiesmarketcap.com/eur/vertex-pharmaceuticals/revenue/

- **[PDF] Investor Presentation** (None)
  https://ir.vertexinc.com/static-files/31abedbd-0bb2-429a-b255-0bfde1a560b0

- **Vertex Pharmaceuticals (VRTX) - Revenue - Companies Market Cap** (None)
  https://companiesmarketcap.com/inr/vertex-pharmaceuticals/revenue/

- **Vertex Pharmaceuticals Net Income 2010-2025 | VRTX - Macrotrends** (None)
  https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/net-income

- **Should You Buy Vertex Pharmaceuticals Stock At $510? - Trefis** (None)
  https://www.trefis.com/investing/articles/563563/should-you-buy-vertex-pharmaceuticals-stock-at-510/2025-03-20

- **VRTX Stock Price Quote - Vertex Pharmaceuticals Inc - Morningstar** (None)
  https://www.morningstar.com/stocks/xnas/vrtx/quote

- **[PDF] Vertex Construction Company - CARE Ratings** (None)
  https://www.careratings.com/upload/CompanyFiles/PR/202412131213_Vertex_Construction_Company.pdf

- **VRTX Stock Price Quote** (None)
  https://www.morningstar.com/stocks/xmex/vrtx/quote

- **Vertex Securities Share Price** (None)
  https://economictimes.indiatimes.com/vertex-securities-ltd/stocks/companyid-5602.cms

- **Pfizer Inc. (NYSE:PFE) | Analysis of Debt** (None)
  https://www.stock-analysis-on.net/NYSE/Company/Pfizer-Inc/Analysis/Debt

- **Erste Group cuts Vertex stock rating to Hold on sales ...** (None)
  https://www.investing.com/news/analyst-ratings/erste-group-cuts-vertex-stock-rating-to-hold-on-sales-concerns-93CH-4062889

- **News** (None)
  https://www.foragerfunds.com/news

- **Vertex Energy (VTNR) Short Interest Ratio and Volume 2025** (None)
  https://www.marketbeat.com/stocks/NASDAQ/VTNR/short-interest/

- **BMO maintains Vertex stock Outperform rating, $557 target** (None)
  https://www.investing.com/news/analyst-ratings/bmo-maintains-vertex-stock-outperform-rating-557-target-93CH-4073466

- **Episode 346 - Hendrik Bessembinder: Why It's So Hard to ...** (None)
  https://rationalreminder.ca/podcast/346

- **Vertex Pharmaceuticals Revenue 2010-2025 | VRTX** (None)
  https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/revenue

- **Vertex Pharmaceuticals Net Income 2010-2025 | VRTX** (None)
  https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/net-income

- **Vertex Pharmaceuticals Gross Profit 2010-2024 | VRTX** (None)
  https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/gross-profit

- **Pfizer Inc. (NYSE:PFE) | Analysis of Debt** (None)
  https://www.stock-analysis-on.net/NYSE/Company/Pfizer-Inc/Analysis/Debt

- **Vertex Announces Fourth Quarter and Full Year 2024** (None)
  https://www.globenewswire.com/news-release/2025/02/27/3033721/0/en/Vertex-Announces-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html

- **News** (None)
  https://www.foragerfunds.com/news

- **Vertex Energy (VTNR) Short Interest Ratio and Volume 2025** (None)
  https://www.marketbeat.com/stocks/NASDAQ/VTNR/short-interest/

- **vertex-announces-fourth-quarter-and-full-year-2024- ...** (None)
  https://www.vertexinc.com/sites/default/files/2025-02/vertex-announces-fourth-quarter-and-full-year-2024-financial-results.pdf

- **Royalty Pharma's Royalty Model: A Fortress of Resilience ...** (None)
  https://www.ainvest.com/news/royalty-pharma-royalty-model-fortress-resilience-volatile-biotech-landscape-2505/

- **The Billion-dollar Molecule Summary PDF | Barry Werth** (None)
  https://www.bookey.app/book/the-billion-dollar-molecule

- **Episode 346 - Hendrik Bessembinder: Why It's So Hard to ...** (None)
  https://rationalreminder.ca/podcast/346

- **Warren Buffett Remains Optimistic About America. Here ...** (None)
  https://www.mitrade.com/au/insights/news/live-news/article-8-827379-20250518

- **Launching Global Best Business Models Version 5** (None)
  https://www.morganstanley.com/content/dam/msdotcom/what-we-do/wealth-management-images/uit/Global-Best-Business-Models-5-Research-Report.pdf

- **Markets News, May 6, 2025: Stocks Fall for 2nd Straight ...** (None)
  https://www.investopedia.com/dow-jones-today-05062025-11728729

- **Investment Reports - Undervalued ...** (None)
  https://www.undervalued-shares.com/reports/investment-reports/

- **102 Warren Buffett Quotes on Life, Success, & More** (None)
  https://www.ruleoneinvesting.com/blog/how-to-invest/warren-buffett-quotes-on-investing-success/

- **Vertex Pharmaceuticals EPS - Earnings per Share 2010- ...** (None)
  https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/eps-earnings-per-share-diluted

- **Vertex Pharmaceuticals (VRTX) - Revenue** (None)
  https://companiesmarketcap.com/eur/vertex-pharmaceuticals/revenue/

- **Vertex Pharmaceuticals (VRTX) - Revenue** (None)
  https://companiesmarketcap.com/inr/vertex-pharmaceuticals/revenue/

- **All Cap Core Strategy 2024-3** (None)
  https://www.invesco.com/us-rest/contentdetail?contentId=666ce0d5-2280-43b1-aa5f-68aaa4909cb8&dnsName=us

- **ANNUAL REPORT** (None)
  https://www.biotechgt.com/application/files/6617/1752/9126/268001_Frostrow_The_Biotech_Growth_Trust_WEB.pdf

- **Vertex Pharmaceuticals Revenue 2010-2025 | VRTX** (None)
  https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/revenue

- **News** (None)
  https://www.foragerfunds.com/news

- **VRTX Institutional Ownership** (None)
  https://www.quiverquant.com/stock/VRTX/institutions/

- **ALYFTREK, JOURNAVX And CASGEVY Will Broaden ...** (None)
  https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/09fwyrng-alyftrek-journavx-and-casgevy-will-broaden-patient-care-options

- **Unsupported Price Increase Report** (None)
  https://icer.org/wp-content/uploads/2024/12/UPI_2024_Report_121224.pdf

- **News** (None)
  https://www.foragerfunds.com/news

- **VRTX - Vertex Pharmaceuticals Inc Latest Stock News & ...** (None)
  https://www.stocktitan.net/news/VRTX/

- **Private Drug Plans in Canada: Expenditure Report, 2018– ...** (None)
  https://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/private-drug-plans-2018-2023.html

- **Episode 346 - Hendrik Bessembinder: Why It's So Hard to ...** (None)
  https://rationalreminder.ca/podcast/346

- **Vertex Reports Third Quarter 2024 Financial Results** (None)
  https://crisprmedicinenews.com/press-release-service/card/vertex-reports-third-quarter-2024-financial-results/

- **abrdn Asian Income Fund Limited** (None)
  https://www.abrdn.com/docs?editionId=18ba1ac8-fafd-4e11-b285-57e763e8b55a

## Usage Stats

- Prompt tokens: 1541
- Completion tokens: 1468
- Total tokens: 3009
- Search queries: 81
